EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

A Randomized Controlled Trial on the Efficacy and Safety of a Calcium-Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor in Chinese and European Patients with Hypertension

Wei Zhang, Chang-Yuan Liu, Grzegorz Bilo iD, Davide Soranna, Antonella Zambon, Konstantinos G Kyriakoulis, Anastasios Kollias iD, Isabella Ceravolo, Silvia Cassago, Martino F Pengo, Antonios Destounis, George S Stergiou und 2 weitere

American Journal of Hypertension · 2025

DOI: 10.1093/ajh/hpae152 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hypertension, 2025. Verfasst von Wei Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hyper…. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Blood Pressure, Calcium Channel Blockers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND In a post hoc analysis of a multinational, randomized trial, we investigated whether the efficacy and safety of nifedipine-gastrointestinal therapeutic system (GITS) and ramipril differed between Chinese and European patients with hypertension. METHODS Previously treated (after 2-week washout) and untreated patients with clinic blood pressure (BP) ≥ 140/90 mmHg (systolic/diastolic), daytime ambulatory BP ≥ 135/85 mmHg and standard deviation of home systolic BP > 7 mmHg, and/or daytime BP > 12 mmHg were randomly assigned to treatment based on nifedipine-GITS 30 mg or ramipril 10 mg for 12 months. Clinic, ambulatory and home BP were measured at baseline, 10 weeks and 12 months after randomization. RESULTS A total of 67 Chinese and 101 European patients were analyzed and they differed in age (50.9 vs. 54.6 years, respectively), body mass index (24.5 vs. 27.0 kg/m2), clinic diastolic BP (87.9 vs. 92.5 mmHg), heart rate (75.0 vs. 70.8 beats/minute), and nighttime diastolic BP (79.3 vs. 75.9 mmHg) (all P < 0.05). However, within each ethnicity, patients were comparable for clinical characteristics between the nifedipine-GITS and ramipril groups (P > 0.05). In both the Chinese and European patients, BP was similarly reduced with nifedipine-GITS and ramipril, except that daytime systolic/diastolic BP reductions were 7.4/4.1 mmHg greater in the ramipril than nifedipine-GITS group in Chinese (P = 0.02). The safety profile differed between the Chinese and European patients (P for drug*ethnicity interaction ≤ 0.05) for all adverse events (lower incidence on nifedipine-GITS in Chinese), ankle edema (higher on nifedipine-GITS in Europeans), and dry cough (higher on ramipril in Chinese). CONCLUSION In the Chinese and European patients with hypertension, nifedipine-GITS and ramipril had similar BP lowering efficacy, but different safety profile and tolerability. CLINICAL TRIALS REGISTRATION Identifier at clinicaltrials.gov NCT02499822 (Registration date: 16 July 2015)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureCalcium Channel BlockersHypertensionNifedipineRamiprilAdultAgedFemaleHumansMaleMiddle AgedChinaDrug Therapy, CombinationEuropeTime FactorsTreatment OutcomeWhite PeopleEast Asian People

Stichwörter der Autor:innen

angiotensin-converting enzyme inhibitorsblood pressurecalcium-channel blockerscoughedemaethnicityhypertensionracial

Substanzen

Angiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel BlockersNifedipineRamipril

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medi…
  • Department of Cardiology, IRCCS, Istituto Auxologic Italliano, San Luca Hospital, Milan, Italy.
  • Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
  • Biostatistics Unit, IRCCS, Istituto Auxologic Italiano, Milan, Italy.
  • Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.
  • Third Department of Medicine, Hypertension Center STRIDE-7, School of Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: Grzegorz Bilo, Anastasios Kollias, Ji-Guang Wang

Zitieren

APA

Zhang, W., Liu, C. Y., Bilo, G., Soranna, D., Zambon, A., Kyriakoulis, K. G., Kollias, A., Ceravolo, I., Cassago, S., Pengo, M. F., Destounis, A., Stergiou, G. S., Wang, J. G., & Parati, G. (2025). A Randomized Controlled Trial on the Efficacy and Safety of a Calcium-Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor in Chinese and European Patients with Hypertension. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpae152

Vancouver

Zhang W, Liu CY, Bilo G, Soranna D, Zambon A, Kyriakoulis KG, et al. A Randomized Controlled Trial on the Efficacy and Safety of a Calcium-Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor in Chinese and European Patients with Hypertension. American Journal of Hypertension. 2025. doi:10.1093/ajh/hpae152

BibTeX
@article{Zhang2025,
  author = {Zhang, Wei and Liu, Chang-Yuan and Bilo, Grzegorz and Soranna, Davide and Zambon, Antonella and Kyriakoulis, Konstantinos G and Kollias, Anastasios and Ceravolo, Isabella and Cassago, Silvia and Pengo, Martino F and Destounis, Antonios and Stergiou, George S and Wang, Ji-Guang and Parati, Gianfranco},
  title = {A Randomized Controlled Trial on the Efficacy and Safety of a Calcium-Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor in Chinese and European Patients with Hypertension},
  journal = {American Journal of Hypertension},
  year = {2025},
  doi = {10.1093/ajh/hpae152}
}
Kostenlos starten →